LETTER IMAJ · VOL 22 · OCTOBER 2020

# Cellulitis and lymphangitis following an injury from a broken cellular phone touch screen

Amir Oron MD

Department of Orthopedics, Hand Surgery Unit, Kaplan Medical Center, Rehovot, Israel

### TO THE EDITOR,

Cellular phones have become the most treasured and trusted companions of 21st century humans. We treated an otherwise healthy 17-year-old female for cellulitis and lymphangitis of the right hand and forearm that started following a laceration to her thumb incurred from the broken touch screen of her cellular phone. Her stubbornness to keep using the phone with a broken screen resulted in her hospitalization for a weekend of intravenous antibiotic treatment. After that weekend, her

condition resolved with no need for surgical intervention.

Cellular phones harbor a myriad of pathogens, primarily Staphylococci and Enterococci [1]. It has been shown that cellular phones used by patients harbor more pathogens than those used by healthcare personnel [2]. The proximity and intimate relations we develop with our cellular devices make them a potential hazard. Although the shift from key-based phones to touch screen phones may have alleviated phenomena such as the Blackberry thumb (if it ever existed) [3], touch screen use may be hazardous in its own right. The number of pathogens on cellular phones may be lowered with the use of alcohol wipes [4]. In these turbulent times of the coronavirus epidemic, medical personnel should put a greater emphasis on cellular phone hygiene [5] and make sure the cellular phone touch screen is intact.

### Correspondence

#### Dr. A. Oron

Dept. of Orthopedics, Kaplan Medical Center, Rehovot 76100, Israel

email: amiroronmd@gmail.com

### References

- Akinyemi KO, Atapu AD, Adetona OO, Coker AO.
   The potential role of mobile phones in the spread of bacterial infections. *J Infect Dev Ctries* 2009; 3 (8):
- Tekerokoglu MS, Duman Y, Serindag A, et al. Mobile phone usage in the clilnical setting: evidence-based guidelines for all users is urgently required. Am J Infect Control 2011; 39 (5): 379-81.
- Karim SA. From "playstation thumb" to "cell phone" thumb: the new epidemic in teenagers. S Afr Med J 2009; 99 (3): 161-2.
- Murgier J, Coste JF, Cavaignac E, et al. Microbial flora on cell-phones in an orthopedic surgery room before and after decontamination. Orthop Traumatol Surg Res 2016; 102 (8), 1093-6.
- Kampf G, Todt D, Pfaender S, Steinman E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J Hosp Infect* 2020; 104 (3): 246-51.

### Capsule

# Modeling SARS-CoV-2 in mice

High on the list of the research tools necessary to develop medical interventions to treat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections are informative animal models with which to study viral pathogenesis. **Gu** et al. developed a mouse model in which a SARS-CoV-2 strain was infectious and could cause an inflammatory response and moderate pneumonia. Adaptation

of this viral strain in the mouse appeared to be dependent on a critical amino acid change, Asn<sup>501</sup> to Tyr (N501Y), within the receptor-binding domain of the viral spike protein. The new mouse model was used to study neutralizing antibodies and a vaccine candidate against the virus.

Science 2020; 369: 1603 Eitan Israeli

## Capsule

# Lovastatin for cardiolaminopathy

Mutations in the gene *LMNA*, which encodes nuclear envelope proteins, can cause dilated cardiomyopathy associated with arrhythmia and sudden cardiac death. To understand the mechanisms contributing to this disease, **Sayed** and colleagues studied induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) from a family harboring an *LMNA* mutation. They found downregulation of a protein involved in mechanotransduction,

which caused endothelial dysfunction. Lovastatin could induce this protein in iPSC-ECs, improving cardiomyocyte function in coculture and clinical endothelial cell function in two patients treated with the drug. This study demonstrates a workflow for identifying and validating potential drug treatments for patients with cardiolaminopathy.

Sci Transl Med 2020; 12: eaax9276 Eitan Israeli